Cargando…

Current and Future Therapeutical Aspects of X-Linked Hypophosphatemia in Children With Special Attention to Klotho/Fibroblast Growth Factor 23 System

Detalles Bibliográficos
Autores principales:	Bittmann, Stefan, Moschuring-Alieva, Elena, Luchter, Elisabeth, Villalon, Gloria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635803/ https://www.ncbi.nlm.nih.gov/pubmed/36406946 http://dx.doi.org/10.14740/jocmr4820

Ejemplares similares

Current Aspects of Treatment Options of Chronic Sialorrhea in Children
por: Bittmann, Stefan, et al.
Publicado: (2022)

Current and Novel Therapeutical Approaches of Classical Homocystinuria in Childhood With Special Focus on Enzyme Replacement Therapy, Liver-Directed Therapy and Gene Therapy
por: Bittmann, Stefan, et al.
Publicado: (2023)

Telemedicine in Pediatrics: Introduction of an Innovative New Tool to Diagnose and Treat Children in an Ambulatory Setting
por: Bittmann, Stefan, et al.
Publicado: (2021)

What Is New With Omicron Variant of SARS-CoV-2 in Children?
por: Bittmann, Stefan, et al.
Publicado: (2022)

Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor?
por: Bittmann, Stefan, et al.
Publicado: (2020)

First Pediatric Case of Autosomal Recessive Homozygotic Bestrophinopathy due to Homozygous Mutation c.187G>C p. in Two Brothers
por: Bittmann, Stefan, et al.
Publicado: (2022)

Parent satisfaction with a pediatric practice in Germany: A questionnaire-based study
por: Weissenstein, Anne, et al.
Publicado: (2011)

FGF23 and its role in X-linked hypophosphatemia-related morbidity
por: Beck-Nielsen, Signe Sparre, et al.
Publicado: (2019)

Fibroblast Growth Factor 23–Induced Hypophosphatemia in Acute Leukemia
por: Reinert, Rachel B, et al.
Publicado: (2018)

Fibroblast growth factor 23, klotho and heparin
por: Thomas, S. Madison, et al.
Publicado: (2023)

Dental management of patients with X-linked hypophosphatemia
por: Lee, Bin-Na, et al.
Publicado: (2017)

Growth Curves for Children with X-linked Hypophosphatemia
por: Mao, Meng, et al.
Publicado: (2020)

Enthesopathy, Osteoarthritis, and Mobility in X-linked Hypophosphatemia
por: Imel, Erik A
Publicado: (2020)

Genotype and Phenotype Analysis in X-Linked Hypophosphatemia
por: Park, Peong Gang, et al.
Publicado: (2021)

Impact of X-Linked Hypophosphatemia on Muscle Symptoms
por: Romagnoli, Cecilia, et al.
Publicado: (2022)

Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia
por: Linglart, Agnès, et al.
Publicado: (2021)

First‐in‐Asian Phase I Study of the Anti‐Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X‐linked Hypophosphatemia
por: Cheong, Hae Il, et al.
Publicado: (2018)

Autism and X-linked hypophosphatemia: A possible association?
por: Joël, Vermeersch, et al.
Publicado: (2010)

SUN-526 Prevalence of Hyperparathyroidism in X-Linked Hypophosphatemia
por: DeLacey, Sean, et al.
Publicado: (2019)

X-Linked Hypophosphatemia: A New Era in Management
por: Dahir, Kathryn, et al.
Publicado: (2020)

X-linked Hypophosphatemia (XLH) Mimicking Rheumatic Disease
por: Takase, Ryosuke, et al.
Publicado: (2020)

Burosumab and Dental Abscesses in Children With X‐Linked Hypophosphatemia
por: Gadion, Margaux, et al.
Publicado: (2022)

Craniosynostosis in Patients With X‐Linked Hypophosphatemia: A Review
por: Munns, Craig F, et al.
Publicado: (2023)

Role of Fibroblast Growth Factor 23 (FGF23) and αKlotho in Cancer
por: Ewendt, Franz, et al.
Publicado: (2021)

Increased prevalence of overweight and obesity in children with X-linked hypophosphatemia
por: Zhukouskaya, Volha V, et al.
Publicado: (2020)

Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population
por: Rodríguez-Rubio, Enrique, et al.
Publicado: (2021)

Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium
por: Laurent, Michaël R., et al.
Publicado: (2021)

Erratum to: “X-Linked Hypophosphatemia: A New Era in Management”
Publicado: (2021)

Serum Levels of Lipocalin Are Lower in Adolescents With X-Linked Hypophosphatemia
por: Simpson, Christine A, et al.
Publicado: (2021)

Health-related quality of life of X-linked hypophosphatemia in Spain
por: Yanes, M. I. Luis, et al.
Publicado: (2022)

Ossification of the Posterior Longitudinal Ligament Caused by X-linked Hypophosphatemia
por: Yamamoto, Koichiro, et al.
Publicado: (2023)

FGF23, Hypophosphatemia, and Emerging Treatments
por: Imel, Erik A, et al.
Publicado: (2019)

Alice in Wonderland syndrome: A rare neurological manifestation with microscopy in a 6-year-old child
por: Weissenstein, Anne, et al.
Publicado: (2014)

Fibroblast growth factor 23—Klotho and hypertension: experimental and clinical mechanisms
por: Freundlich, Michael, et al.
Publicado: (2020)

Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia
por: Ruppe, Mary D., et al.
Publicado: (2016)

Burosumab in X-linked hypophosphatemia: a profile of its use in the USA
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

Correction to: Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population
por: Rodríguez-Rubio, Enrique, et al.
Publicado: (2021)

Clinical and Genetic Characteristics of 153 Chinese Patients With X-Linked Hypophosphatemia
por: Lin, Xiaoyun, et al.
Publicado: (2021)

Corrigendum: Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium
por: Laurent, Michaël R., et al.
Publicado: (2021)

An Evidence-based Physical Therapy Prescription for Adults With X-linked Hypophosphatemia
por: Kanamalla, Karthik, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ch0eipgn4dh4f7cqnviagltbir